Publications

An up-to-date list of our Journal publications can be found on PubMed or Google Scholar.

Recent Significant Publications

 

Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer
Cancer Discovery 2018
Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN

 

Liquid vs Solid Biopsy

 

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Journal of the National Cancer Institute 2017
Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME

 

Vandekerkhove et al. 2017

 

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Clinical Cancer Research 2017
Vandekerkhove G, Todenhöfer T, Annala M, Struss WJ, Wong A, Beja K, Ritch E, Brahmbhatt S, Volik SV, Hennenlotter J, Nykter M, Chi KN, North S, Stenzl A, Collins CC, Eigl BJ, Black PC, Wyatt AW.

 

Annala et al., 2017

 

Treatment outcomes and tumor loss-of-heterozygosity in germline DNA repair deficient prostate cancer
European Urology 2017
Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW

 

Genomic alterations in ctDNA

 

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
JAMA Oncology 2016
Wyatt AW
, Azad AA, Volik SV, Annala M, Beja K, McConeghy B, Haegert A, Warner EW, Mo F, Brahmbhatt S, Shukin R, Le Bihan S, Gleave ME, Nykter M, Collins CC, Chi KN.

 

All Recent Journal Articles

2018

Annala M, Taavitsainen S, Vandekerkhove G, Bacon JVW, Beja K, Chi KN, Wyatt AW. Frequent mutation of the FOXA1 untranslated region in prostate cancer. Communications Biology 1, Article number: 122 (2018)

Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. J Natl Compr Canc Netw. 2018 Aug;16(8):933-937. PMID: 30099369.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 Jul 26;174(3):758-769.e9. PMID: 30033370

Chedgy EC†, Vandekerkhove G†, Herberts C†, Annala M, Donoghue AJ, Sigouros M, Ritch E, Struss W, Konomura S, Liew J, Parimi S, Vergidis J, Hurtado-Coll A, Sboner A, Fazli L, Beltran H, Chi KN, Wyatt AW. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. J Pathol. 2018 Jul 17. doi: 10.1002/path.5137. [Epub ahead of print] PMID: 30015382

Park ES, Yan JP, Ang RA, Lee JH, Deng X, Duffy SP, Beja K, Annala M, Black PC, Chi KN, Wyatt AW, Ma H. Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection. Lab Chip. 2018 Jun 12;18(12):1736-1749. PMID: 29762619

Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. 2018 Jun 1;7(6). PMID: 29757368

Goriki A, Seiler R, Wyatt AW, Contreras-Sanz A, Bhat A, Matsubara A, Hayashi T, Black PC. Unravelling disparate roles of NOTCH in bladder cancer. Nat Rev Urol. 2018 Jun;15(6):345-357. PMID: 29643502

Todenhöfer T, Struss WJ, Seiler R, Wyatt AW, Black PC. Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. Bladder Cancer. 2018 Jan 20;4(1):19-29. PMID: 29430504

Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW*, Chi KN*. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018 [Epub ahead of print]. PMID: 29367197. *co-corresponding authors

Todenhöfer T, Struss WJ, Seiler R, Wyatt AW, Black PC. Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. Bladder Cancer. 2018. [Epub ahead of print]. PMID: 29430504.

2017

Ritch E, Wyatt AW. Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA. Urol Oncol. 2017 [Epub ahead of print]. PMID: 29248429.

Wyatt AW†*, Annala M†, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx118. PubMed PMID: 29206995. co-first authors; *corresponding author

Vandekerkhove G, Chi KN, Wyatt AW. Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Cancer Genet. 2017 [Epub ahead of print]. PMID: 28958406

Beltran H†, Wyatt AW†, Chedgy EC, Donoghue A, Annala M, Warner EW, Beja K, Sigouros M, Mo F, Fazli L, Collins CC, Eastham J, Morris M, Taplin ME, Sboner A, Halabi S, Gleave ME. Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clin Cancer Res. 2017 [Epub ahead of print]. PMID: 28842510. co-first authors

Vandekerkhove G†, Todenhöfer T†, Annala M†, Struss WJ, Wong A, Beja K, Ritch E, Brahmbhatt S, Volik SV, Hennenlotter J, Nykter M, Chi KN, North S, Stenzl A, Collins CC, Eigl BJ, Black PC, Wyatt AW. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clin Cancer Res. 2017 Nov 1;23(21):6487-6497. PMID: 28760909

Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 Sep;7(9):999-1005. PMID: 28450426

Annala M†, Struss WJ†, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW. Treatment outcomes and tumor loss-of-heterozygosity in germline DNA repair deficient prostate cancer. Eur Urol. 2017 Jul;72(1):34-42. PMID: 28259476. †co-first authors

Kiss B, Wyatt AW, Douglas J, Skuginna V, Mo F, Anderson S, Rotzer D, Fleischmann A, Genitsch V, Hayashi T, Neuenschwander M, Bürki C, Davicioni E, Collins C, Thalmann GN, Black PC, Seiler R. Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Sci Rep. 2017 Feb 16; 7:42713. PMID: 28205537

Donmez N, Malikic S, Wyatt AW, Gleave ME, Collins CC, Sahinalp SC. Clonality inference from single tumor samples using low-coverage sequence data. J Comput Biol. 2017 Jan 5 [Epub ahead of print]. PMID: 28056180

2016

Holt R, Ugur Iseri SA, Wyatt AW, Bax DA, Gold Diaz D, Santos C, Broadgate S, Dunn R, Bruty J, Wallis Y, McMullan D, Ogilvie C, Gerrelli D, Zhang Y, Ragge N. Identification and functional characterisation of genetic variants in OLFM2 in children with developmental eye disorders. Hum Genet. 2016 Nov 14. [Epub ahead of print]. PMID: 27844144.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A. The Master Neural Transcription Factor BRN2 is an Androgen Receptor Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discov. 2016 Oct 26. pii: CD-15-1263. [Epub ahead of print]. PMID: 27784708.

Saranchova I, Han J, Huang H, Choi KB, Munro L, Pfeifer C, Welch I, Wyatt AW, Fazli L, Gleave ME, Jefferies WA. Discovery of a Novel Mechanism of Cancer Immune Escape Guided by the Loss of Interleukin-33 Expression. Sci Rep. 2016 Sep 13;6:30555. PMID: 27619158.

Lowes LE, Bratman SV, Dittamore R, Done S, Kelley SO, Mai S, Morin RD, Wyatt AW, Allan AL. Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J Mol Sci. 2016 Sep 8;17(9). pii: E1505. PMID: 27618023.

Kockan C, Hach F, Sarrafi I, Bell RH, McConeghy B, Beja K, Haegert A, Wyatt AW, Volik SV, Chi KN, Collins CC, Sahinalp SC. SiNVICT: Ultra-Sensitive Detection of Single Nucleotide Variants and Indels in Circulating Tumour DNA. Bioinformatics 2016 [Epub ahead of print]. PMID: 27531099.

Annala M, Nappi L, Azad AA, Mo F, Fazli L, Chi KC, Wyatt AW. Molecular dissection of complete response to receptor tyrosine kinase inhibition in type II papillary renal cell carcinoma. Clinical Genitourinary Cancer 2016. pii: S1558-7673(16)30145-8.

Wyatt AW†, Azad AA†, Volik SV†, Annala M, Beja K, McConeghy B, Haegert A, Warner EW, Mo F, Brahmbhatt S, Shukin R, Le Bihan S, Gleave ME, Nykter M, Collins CC, Chi KN. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncology 2016. 2(12):1598-1606. PMID: 27148695. co-first authors

Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, Chi KN, Gleave ME, Rennie PS, Collins CC, Cherkasov A. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biology 2016. 17(1):10. PMID:26813233.

Hayashi T, Gust KM, Wyatt AW, Goriki A, Jäger W, Awrey S, Li N, Oo HZ, Altamirano-Dimas M, Buttyan R, Fazli L, Matsubara A, Black PC. Not all Notch is created equal: the oncogenic role of NOTCH2 in bladder cancer and its implications for targeted therapy. Clinical Cancer Research 2016. PMID: 26769750. (Epub ahead of print).

Chedgy ECP, Annala M, Beja K, Warner EW, Gleave ME, Chi KN, Wyatt AW. Moving towards personalized care: liquid biopsy predicts response to cisplatin in an unusual case of BRCA2-null neuroendocrine prostate cancer. Clinical Genitourinary Cancer 2016. 14(2):e233-6. PMID: 26797585

2015

Akamatsu S†, Wyatt AW†, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, Brahmbhatt S, Bell R, Adomat H, Fazli L, Kawai Y, Xue H, Dong X, Fazli L, Tsai H, Lotan TL, Kossai M, Mosquera JM, Rubin MA, Beltran H, Zoubeidi A, Wang Y, Gleave ME, Collins CC. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Reports 2015. Aug 11;12(6):922-36. PMID:26235627. co-first authors

Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, Saad F. Treatment of mCRPC in the AR axis-targeted therapy resistant state. Annals of Oncology 2015 Oct; 26(10):2044-56. PMID: 26101426.

Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, Anderson S, Moskalev I, Haegert A, Alshalalfa M, Erho N, Davicioni E, Fazli L, Li E, Collins C, Wang Y, and Black PC. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget 2015 Aug 28;6(25):21522-32. PMID: 26041878.

Wyatt AW, Gleave ME. Targeting the adaptive molecular landscape of castration resistant prostate cancer. EMBO Molecular Medicine 2015 Apr 20;7(7):878-94. PMID: 25896606.

Azad AA†, Volik SV†, Wyatt AW†, Haegert A, Le Bihan S, Bell RH, Anderson S, McConeghy B, Shukin R, Bazov J, Youngren J, Paris PL, Thomas GV, Small EJ, Wan Y, Gleave ME, Collins CC, Chi KN. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance and response in castration-resistant prostate cancer. Clin Cancer Res 2015 May 15;21(10):2315-24. PMID: 25712683. †co-first authors

Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, Al Nakouzi N, Mo F, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli F, Collins CC, Zoubeidi A, Gleave ME. Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and its Splice Variants Suppress Enzalutamide Resistant Prostate Cancer Cell Growth. Clin Cancer Res. 2015 Apr 1;21(7):1675-87. PMID: 25634993.

Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang Y, Wu R, Bell RH, Haegert A, Brahmbhatt S, Hurtado-Coll A, Gout PW, Fazli L, Gleave ME, Collins CC, Wang Y. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget. 2015 Jan 30;6(3):1806-20 PMID: 25544761.

2014

Wyatt AW, Mo F, Wang K, McConeghy B, Brahmbhatt S, Jong L, Mitchell DM, Johnston RL, Haegert A, Li E, Liew J, Yeung J, Shrestha R, Lapuk A, McPherson A, Shukin R, Bell RH, Anderson S, Bishop J, Hurtado-Coll A, Xiao H, Chinnaiyan A, Mehra R, Lin D, Wang Y, Fazli L, Gleave ME, Volik SV, Collins CC. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol 2014 Aug 26;15(8):426. PMID: 25155515.

Mo F, Wyatt AW, Sun Y, Brahmbhatt S, Wu C, Wang Y, Gleave ME, Volik SV, Collins CC. Systematic identification and characterization of RNA editing in prostate tumors. PLoS One 2014 Jul 18;9(7):e101431. doi: 10.1371/journal.pone.0101431. eCollection 2014. PMID: 25036877. co-first authors

Wang K, Shrestha R, Wyatt AW, Reddy A, Lehár Y, Wang Y, Lapuk A, Collins CC. A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines. PLoS One. 2014 Jul 18;9(7):e103050. PMID: 25036042.

Govind SK, Zia A, Hennings-Yeomans PH, Watson JD, Fraser M, Anghel C, Wyatt AW, van der Kwast T, Collins CC, McPherson JD, Bristow RG, Boutros PC. ShatterProof: operational detection and quantification of chromothripsis. BMC Bioinformatics 2014 Mar 19;15:78. PMID: 24646301.

Lin D, Xue H, Wang Y, Wu R, Watahiki A, Dong X, Cheng H, Wyatt AW, Collins CC, Gout PW, Wang YZ. Next generation patient-derived prostate cancer xenograft models. Asian J Androl. 2014 May-Jun;16(3):407-12. PMID: 24589467.

Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt B, Mo F, Jong L, Bell RH, Anderson S, Hurtado-Coll A, Fazli L, Sharma M, Beltran H, Rubin M, Cox M, Gout PW, Morris J, Goldenberg L, Volik SV, Gleave ME, Collins CC, Wang Y. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Research 2014 Feb 15;74(4):1272-83. PMID: 24356420. co-first authors

 

Top

Spam prevention powered by Akismet